相关实验视频

Updated: Jun 9, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

利用线粒体编程细胞死亡动态来提高预后准确性和肺腺癌免疫疗法的疗效

Lianmin Zhang¹, Yanan Cui², Guangyao Zhou¹

¹Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Journal for immunotherapy of cancer

|October 25, 2024

概括

这项研究开发了一种新的线粒体相关的编程细胞死亡特征 (MPCDS),以预测肺腺癌 (LUAD) 患者的结果和免疫治疗的反应. 鉴定出NME4基因是免疫排除的关键驱动因素,为LUAD提供了潜在的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

肺腺癌 (LUAD) 是一种异质性癌症,具有具有挑战性的预后预测.
线粒体和编程细胞死亡 (PCD) 在癌症中至关重要,但它们在LUAD中的相互作用需要澄清.

研究的目的:

根据与线粒体相关的PCD开发LUAD的预后特征.
研究这种特征及其关键基因在免疫逃避和治疗反应中的作用.

主要方法:

机器学习被用来从1231名LUAD患者中创建与线粒体相关的PCD签名 (MPCDS).
在免疫治疗队列和泛癌队列中验证了MPCDS. 在实验室和体内探索了NME4的作用.

主要成果:

该MPCDS准确地预测了LUAD预后和免疫治疗结果,性能优于现有的签名.
高MPCDS得分与免疫活性降低和感冒瘤相关.
在LUAD中,NME4表达与预后不佳和免疫排除有关,调节瘤生长和入侵.

结论:

该MPCDS提供个性化风险评估,并为LUAD患者提供免疫治疗指南.
NME4是一种促进免疫排除的新型瘤基因,也是LUAD干预和免疫治疗的潜在治疗点.

关键词:

生物标志物生物标志物免疫治疗是一种免疫疗法.肺癌肺癌是一种肺癌.瘤微环境瘤微环境

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.